- Meeting abstract
- Open Access
P01-043 – Comparative characteristic of FMF and FMF with HSP
© Sargsyan and Ghazaryan; licensee BioMed Central Ltd. 2013
- Published: 8 November 2013
- Public Health
- Clinical Study
- Lipid Peroxidation
- Sharp Increase
According the literature data about Familial Mediterranean Fever (FMF), with the combination of Henoch- Sheilen purpura (HSP), as well as the results of the work done by the former of our studies we attempt to identify and compare membranes aspects of pathogeneses of FMF and combination of FMF with HSP.
The aim of our study is to identify speed of lipid peroxidation (LPO) and the role of degradation of membrane phospholipids (PL) of FMF and combination of FMF with HSP.
Clinical studies conducted in 61 non complicated of amyloidosis FMF children in the Republican FMF Children Center, Center “Arabkir”. The age of the patients varies from 5-15. Three patients of FMF are accompanied with HSP. We are selected as a control group of 11 healthy people in practice.Biochemical studies carried out in Hematological Center of Armenia. In erythrocytes of membrane we determine the following index: phospholipase A2 activity, intensity of LPO, as well as the level of citotoxic - Lysophatidylcholines( LysoPCH ). The activity of phospholipase A2 and LPO was determined by the spektrofotometrik methods. The fractions of separate PL in erythrocyte membranes were carried out by thin-layer chromatography methods.
The results of our research showed that FMF is followed by rising the activity of phospholipase A2 (approximately two times, P<0,001), with sharp increase of citotoxic- LysoPCH (P<0,001) and intensity of LPO (about 3 times, P <0,001).It is noteworthy, that in the second group of our patients (FMF with HSP) these indices will be raised. Therefore, the mentioned follows that the second group of patients treatment is more difficult and requires a special, single-minded approach.
The results in our experience are discussed to find possible ways of increasing efficiency of treatment FMF with HSP.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.